• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SNT
Click for more information
15.0% 6.9¢

SYNTARA LIMITED - Charts / Financials

Market Cap $41.29M  ! watchlist Created with Sketch. Add to my watchlist

Syntara Limited is an Australia-based clinical-stage drug development company. The... Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 15.58pm 03/12/2024 (20 minute delay) ?
Day
Open 6.0¢   Day High 6.9¢   Day Low 5.9¢
Daily Volume 11225253
Bids   Sellers
Number Price Volume   Number Price Volume
6 6.5¢ 900000   3 6.9¢ 219035

Directors & Senior Management

Mr. Gary Jonathan Phillips Chief Executive Officer, Managing Director, Executive Director
Mr. David Morris Mcgarvey Chief Financial Officer, Company Secretary
Dr. Jana Baskar Chief Medical Officer
Mr. Wolfgang G. Jarolimek Head - Drug Discovery
Ms. Kristen Morgan Alliance Management and Head - Medical and Regulatory Affairs
Dr. Kathleen Mary Metters Non-Executive Chairman of the Board
Mr. Waradana Malitha Hashan De Silva Non-Executive Director
Dr. Simon P. Green Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
6.9¢ 		Change
0.009(15.0%) 		Mkt cap ! $41.29M
Open High Low Value Volume
6.0¢ 6.9¢ 5.9¢ $699.0K 11.22M

Buyers (Bids)

No. Vol. Price($)
6 900000 6.5¢
 

Sellers (Offers)

Price($) Vol. No.
6.9¢ 219035 3
View Market Depth
Last trade - 16.10pm 03/12/2024 (20 minute delay) ?
Last
6.9¢ 		  Change
0.009 ( 15.0 %)
Open High Low Volume
6.0¢ 6.9¢ 5.8¢ 1157154
Last updated 15.58pm 03/12/2024 ?

Top Stories

Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising!

Companies can now raise capital through HotCopper! It’s a development allowing a highly cost-effective service to ASX-listed companies, while opening new investment opportunities to investors.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.